Evolus, Inc. ( (EOLS) ) has released its Q3 earnings. Here is a breakdown of the information Evolus, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evolus, Inc. is a global performance beauty company specializing in aesthetic injectables, with a focus on consumer-centric products and innovative digital platforms. The company is known for its flagship products, Jeuveau® and Evolysse™, which are designed to redefine the aesthetic injectable market.
Evolus reported a strong third quarter for 2025, with total net revenue of $69.0 million, marking a 13% increase from the same period in 2024. The growth was driven by the performance of its products, Jeuveau® and the newly launched Evolysse™, which has been noted as the most successful hyaluronic acid filler debut in over a decade.
Key financial highlights include a global Jeuveau® net revenue of $63.2 million, an increase from the previous quarter, and Evolysse™ generating $5.7 million in revenue. The company also reported a reduction in non-GAAP operating expenses, contributing to a non-GAAP loss from operations of $3.1 million, an improvement from the previous year. Evolus has successfully increased its market share in the U.S. and expanded its customer base, with significant growth in its consumer loyalty program.
Looking ahead, Evolus expects to achieve positive non-GAAP operating income in the fourth quarter of 2025 and aims for sustainable annual profitability starting in 2026. The company reaffirms its revenue guidance for 2025 and plans to expand its product distribution and engagement with core customers, positioning itself for continued growth and profitability.
Evolus remains focused on balancing growth with operational discipline, aiming for a total net revenue of $700 million by 2028. The company is also preparing for new product launches and actively monitoring potential impacts from tariffs, ensuring its strategies align with market developments and shareholder value creation.